In a placebo-controlled, double-blind crossover study of 14 male chronic
schizophrenic patients, high doses of the opiate antagonist naloxone were
given intravenously. Hallucinations measured on a verbal- report scale were
significantly decreased after naloxone administration. The authors suggest
that this apparent action of naloxone is mediated by central opiate
receptors and that it may result from an interaction between central
endorphin systems and central catecholaminergic neurons.Abstract Teaser